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INTRODUCTION
Colorectal cancer is one of the most
common malignancies worldwide. De-
spite the improvement in its prognosis
and therapy in the last few decades,
nearly one-half of colorectal cancers re-
lapse from metastasis after curative sur-
gery (1). It is essential to develop new tar-
gets and therapeutic approaches, and
therapeutic target development requires
identification of novel functional mole-
cules, their mechanisms of action and
strategies for intervention (2). S100P is a
95–amino acid residue protein that is a
member of the S100 family. The protein
was first purified from placenta with a re-
stricted cellular distribution (3). S100 pro-
teins consist of Ca2+ binding proteins of
the elongation factor (EF)-hand type that
mediate Ca2+-dependent signal transduc-
tion pathways involved in the regulation
of a number of cellular processes such as
cell cycle progression and differentiation
(4). Overexpression of S100P was ob-
served in various cancers, including pan-
creatic (5), breast (6), colon (7), prostate
(8) and lung carcinomas (9). S100P was
also reported to correlate with tumor
growth and metastasis in breast (6,10,11),
colon (12) and pancreatic (3) cancer.
S100P ectopic expression in a non-
metastatic rat mammary cell line caused
a notable increase in local muscle inva-
sion and a significant induction of metas-
tasis in tumor-bearing animals (10). Gene
transfer or extracellular addition of S100P
increased tumor growth and metastasis,
and silencing of S100P resulted in the re-
duction of the tumor growth and second-
ary meta static volume in models of pan-
creatic cancer (3). Extracellular S100P
interacts with the receptor of advanced
glycation end products (RAGE), which is
associated with various cancers and stim-
ulates Erk and nuclear factor (NF)-κB ac-
tivity (13). Overexpression of S100P in
pancreatic cancer Panc-1 cells protects
cancer cells against cell death induced by
chemotherapeutic 5-fluorouracil (5-FU)
(3) and leads to increased S100A6 and
cathepsin D expression, both of which are
involved in cellular invasion (14). S100P
also appears to function to increase gas-
tric cancer growth and invasion of the
cancer cells (15). Despite recent advances
in understanding the biology of S100P,
the functional role or mechanism of ac-
tion of S100P in colon cancer is poorly
understood. Fuentes et al. (12) showed
that S100P is specifically expressed in
human colon cancer tissue but not in nor-
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mal colon tissue, and exogenous S100P
increases colon cancer SW480 cell prolif-
eration and cell migration in vitro and up-
regulates Erk phosphorylation and NFκB
activation. Thus, it appears that S100P is
a potential therapeutic target for colon
cancer.
In the present study, we investigated
the functional role and molecular mecha-
nisms of S100P activity in colon cancer.
We found that knockdown of S100P ex-
pression by lentiviral vector–mediated
RNA interference (RNAi) inhibited colon
cancer cell growth, migration and inva-
sion in vitro, as well as tumor growth
and liver metastasis in vivo. Furthermore,
thioredoxin 1 (trx-1), β-tubulin and Rho
GDP dissociation inhibitor α (RhoGDIA)
were identified as S100P downstream
target proteins in colon cancer cells by
proteomic analysis.
MATERIALS AND METHODS
Cell Culture
Colon cancer cell lines DLD-1 and
SW620 were used for the present study.
All cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with
10% fetal bovine serum (Invitrogen,
Carlsbad, CA, USA) supplemented with
100 U/mL penicillin and 100 μg/mL
streptomycin at 37°C in a humidified 5%
CO2 incubator.
Lentiviral shRNA Vector Construction,
Production and Transduction
Lenti-shRNA vector construction was
done as previously described (16).
Briefly, we synthesized DNA fragments
containing GAC AGC ACA as the loop
for short-hairpin RNA (shRNA) and
cloned the shRNA targeting human
S100P (5′-AAC TCA CTG AAG TCC
ACC TGG GCA TCT CC-3′) into human
U6 promoter–containing pBluescript
SK(+) plasmid (pU6) after annealing.
Then we subcloned the U6-shRNA cas-
settes into the lentiviral vector (16). A
lentivirus carrying shRNA-targeting fire-
fly luciferase (shLuc: 5′-TGC GCT GCT
GGT GCC AAC CCT ATT CT-3′) was
used as the control. Lentiviral packaging
and transduction were carried out as pre-
viously described (16).
Reverse Transcription and
Quantitative Real-Time Polymerase
Chain Reaction
Total RNA was isolated using Trizol
(Invitrogen), and cDNA synthesis was
performed using a Superscript First-
Strand Synthesis Kit (Promega, Madison,
WI, USA) (17). The quantification of
mRNA levels was carried out using
SYBR® Green PCR Master Mix (Applied
Biosystems, Warrington, UK; PCR, poly-
merase chain reaction) and an ABI 7500
Real-Time PCR System (Applied Biosys-
tems). The following forward and re-
verse primers were used: S100P, 5′-ATG
ACG GAA CTA GAG ACA GCC ATG
GGC-3′ and 5′-GGA ATC TGT GAC ATC
TCC AGG GCA TCA-3′ (12); GAPDH, 5′-
CCA GCC GAG CCA CAT CGC TC-3′
and 5′-ATG AGC CCC AGC CTT CTC
CAT-3′. The relative expression of S100P
was normalized to that of GAPDH, an
endogenous housekeeping gene.
Western Blot
The SDS-PAGE and Western blot analy-
sis was performed as described (17). The
primary antibodies used were polyclonal
antibodies against S100P, β-tubulin, thio -
redoxin, RhoGDIA and actin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA).
Cell Proliferation and Colony
Formation Assays
Cell proliferation was measured using
a methylthiazoletetrazolium (MTT) assay
(17). For colony formation assay, 5,000
cells in complete DMEM were seeded
onto 10-cm culture dish and allowed to
grow for 14 d to form colonies, which
were then stained with coomassie blue.
The rate of colony formation was calcu-
lated with the following equation: colony
formation rate = (number of colonies/
number of seeded cells) × 100%.
Culture of Colon Cancer Cells in
Three-Dimensional Collagen Gels
A total of 5,000 cells were collected
and resuspended in a 2-mL solution
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Figure 1. Efficient knockdown of S100P expression by lentiviral vector–mediated RNAi in
DLD-1 and SW620 colon cancer cells lines. (A, B) Decreases in S100P mRNA level in DLD-1
and SW620 cells transduced with lenti-shS100P revealed by real-time RT-PCR. (C, D) De-
creases in S100P protein levels in DLD-1 and SW620 cells transduced with lenti-shS100P
 revealed by Western blotting. shLuc, colon cancer cells transduced with lenti-shLuc;
shS100P, colon cancer cells transduced with lenti-shS100P.
 containing complete DMEM, rat tail
collagen I (BD Biosciences, Franklin
Lakes, NJ, USA), to support the growth
of cells in a three-dimensional matrix
(18). The solution was added into six-
well plates and incubated for 30 min at
37°C until a homogenous gel was
formed. The culture medium was
added to the space surrounding colla-
gen I gel embedded with cells and re-
plenished every 2 d. After 14 d, results
were observed and photo graphed. The
number of spheroids was counted at 
20 random fields with magnification 
of 40×.
Wound Healing and Cell Invasion
Assays
A wound-healing assay was per-
formed as described (14). Assayed cells
(1 × 106) were seeded on a six-well plate
and cultured for 24 h. A scratch was
made on the cell monolayer with a
200-μL pipette tip. The photographs were
taken immediately and at 72 h after
wounding. A 48-well Boyden chamber
and polycarbonate membrane precoated
with matrigel (BD Biosciences) with
10-μm pores (Neuro Probe, Gaithersburg,
MD, USA) was used to evaluate the can-
cer cell invasion ability (19). DMEM with
10% fetal bovine serum was added to the
lower compartment as a chemoattractant.
DLD-1 or SW620 (4 × 104) suspended in
50 μL DMEM with 0.5% BSA was loaded
onto the upper compartment of each
chamber. After incubation in a humidi-
fied atmosphere of 5% CO2 at 37°C for
13 h (DLD-1 cells) or 38 h (SW620 cells),
the cells on the upper surface of the
membrane were gently scraped off, and
the cells on the bottom surface of the
membrane were fixed with 4% para -
formaldehyde and stained with hema-
toxylin. Images were captured using a
microscope at a ×100 magnification, and
invasion cells were counted in 10 ran-
dom selected fields. All experiments
were done in triplicate.
Tumor Growth and Liver Metastasis
Model in Nude Mice
Six-week-old male athymic nude mice
were purchased from the Animal
House, Chinese University of Hong
Kong. All experiments were approved
by the Animal Experimental Ethics
Committee of the Chinese University of
Hong Kong. Nude mice were injected
subcutaneously with 1 × 106 DLD-1 cells
transduced with lenti-shLuc or lenti-
shS100P. The volumes of tumors were
monitored at the indicated times and
calculated according to the formula: 
0.5 × length × width2. In vivo liver
metastatic capability of colorectal cancer
cells was evaluated in athymic nude
mice (n = 10/each group) as described
previously (20). Briefly, a small left ab-
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Figure 2. Knockdown of S100P by lentiviral vector–mediated RNAi inhibited colon cancer cell growth and colony formation. (A, B) S100P
knockdown caused a significant growth inhibition of colon cancer cells as revealed by MTT assay. (C, D) S100P knockdown inhibited can-
cer cell colony formation; representative images from triplicate experiments were shown. shLuc versus blank: P > 0.05; shS100P versus
shLuc: **P < 0.01. OD, optical density.
dominal incision was made under ster-
ile conditions and spleen was exterior-
ized. Control or S100P knockdown
DLD-1 cells (1 × 106) in 0.1 mL PBS were
injected into the spleen by means of a
sterile tuberculin syringe and a 27-
gauge needle. Ten minutes after the in-
jection, a splenectomy was performed.
The abdomen was closed with nylon
 sutures. After 6 wks, the animals were
euthanized and liver metastases were
examined.
Proteomic Analysis
The procedures were carried out as de-
scribed previously (16,19). Briefly, for the
first dimension, immobilized pH gradi-
ent (IPG) strips (13 cm, pH 4–7, nonlin-
ear [NL]) were used according to the
manufacturer’s instructions. The second
dimension was run in 12.5% uniform
sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) gel for
protein separation. Thereafter, the pro-
tein spots were visualized by silver stain-
ing. All gel images were digitalized
using a scanner (GS-800 calibrated den-
sitometer; Bio-Rad, Hercules, CA, USA)
with the Quantity One software (Bio-
Rad). All images were analyzed using
PDQuest (version 8.0, Bio-Rad) for spot
detection and quantification. Spots of in-
terest were selected and excised from the
gels for identification. Protein identifica-
tion was achieved by matrix- assisted
laser desorption/ ionization time-of-flight
mass spectrometry (MALDI-TOF MS)
using a 4700 Proteomics Analyzer
(TOF/TOF) (Applied Biosystems). Pep-
tide mass mapping was carried out using
the program MASCOT (Matrix Science,
London, UK) against an NCBInr data-
base with a GPS explorer software (Ap-
plied Biosystems). Tryptic autolytic frag-
ments and notable contamination were
excluded from the peak lists before the
database search.
Statistical Analysis
Data are expressed as mean ± SD in
this study. Statistical analysis was per-
formed by using the independent sam-
ples t test (SPSS Inc., Chicago, IL, USA).
P values <0.05 were considered statisti-
cally  significant.
RESULTS
Efficient Knockdown of S100P
Expression by Lentiviral
Vector–Mediated RNAi in Colon
Cancer Cells
To examine the effect of blocking
S100P expression by lentiviral vector–
mediated RNAi, real-time PCR and
Western blot analysis were performed
on DLD-1 and SW620 colon cancer cells.
As shown in Figure 1A, S100P mRNA
expression was reduced by 90% after
lenti-shS100P infection in DLD-1 cells,
but control lenti-shLuc did not alter
S100P expression. The protein expres-
sion diminished to barely detectable lev-
els in the DLD-1 cells infected with
lenti-shS100P, compared with the cells
infected with the control lenti-shLuc or
the uninfected blank cells (Figure 1C).
Similar data were achieved in SW620
cells after lenti-shS100P infection (Fig-
ure 1B, D).
RNAi-Mediated Knockdown of S100P
Suppressed Colon Cancer Cell
Proliferation In Vitro
As revealed by MTT assay, S100P
knockdown significantly reduced cell
proliferation of colon cancer DLD-1 and
SW620 cells (Figure 2A, B). As shown in
Figure 2C and D, DLD-1 and SW620 cells
infected with lenti-shS100P showed sig-
nificant reduction in the colony forma-
tion. No apparent difference was found
between the parental cells and the con-
trol cells (which were infected with lenti-
shLuc). Moreover, Figure 3A and B
showed the images of colon cancer
DLD-1 and SW620 cell growth in a three-
dimensional culture model. There was a
clear decrease in both the size and num-
ber of spheroids (Figure 3A and Fig-
ure 4D) in cells with lenti-shS100P com-
pared with the control cells. These results
indicate a positive correlation between
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Figure 3. Knockdown of S100P inhibited colon cancer DLD-1 and SW620 cell growth in a
three-dimensional culture model. (A, B) Phase contrast micrographs of DLD-1 and SW620
cell growth in a three-dimensional culture at a magnification of 40 or 200, scale bar = 
200 μm. Typical photographs were shown. (C, D) Mean number of spheroids/field was cal-
culated (n = 20, 40×). Values are mean ± SD. **P < 0.01.
the expression of S100P and the rate of
colon cancer cell growth.
Knockdown of S100P Inhibited Colon
Cancer Cell Migration and Invasion
In Vitro
The effect of S100P on colon cancer cell
migration and invasion was investigated
by using a monolayer wound healing and
chamber assays. As shown in Figure 4A,
DLD-1–shS100P cells after a wound
scratch significantly inhibited the ratio of
wound sealing compared with the con-
trol DLD-1–shLuc cells. In addition,
knockdown of S100P inhibited colon can-
cer cell invasion through matrigel-coated
membranes (Figure 4B).
RNAi Targeting S100P Inhibited Tumor
Growth and Liver Metastasis of Colon
Cancer In Vivo
Tumor formation was compared be-
tween DLD-1–shLuc and DLD-1– shS100P
cells in nude mice. Cells were inoculated
in nude mice, and tumor growth was
measured after 6 wks. As shown in Fig-
ure 5A and B, tumor formation was ob-
served in all mice inoculated with 
DLD-1–shLuc or DLD-1–shS100P cells,
while knockdown of S100P in DLD-1
cells showed a decrease in the size of tu-
mors when compared with its control
counterpart (Figure 5A). Moreover, Fig-
ure 5C shows the macroscopic appearance
of liver metastasis after intrasplenic injec-
tion of colon cancer DLD-1 cells into the
athymic nude mice spleen. Some macro-
scopic nodules (that is, metastasis) were
found at the liver surface 6 wks after in-
jection with DLD-1– shLuc cells and in 5
of 10 mice with macroscopic nodules
(50% liver metastasis), whereas no macro-
scopic nodule was found at the liver sur-
face after injection with DLD-1–shS100P
cells in spleen.
Proteomic Analysis of S100P
Downstream Target Proteins in Colon
Cancer Cells
Image analysis using the PDQuest
two-dimensional software identified 30
protein spots that displayed differential
expression among DLD-1 transduced
with lenti-shLuc and lenti-shS100P (Fig-
ure 6). Subsequently, each spot was ana-
lyzed and 24 S100P-associated proteins
were identified by MALDI-TOF MS
(Table 1). These proteins were all differ-
entially expressed at least two-fold (ei-
ther increased or decreased) when the
comparison between the control and the
S100P knockdown colon cancer DLD-1
cells was made. Of these, 15 were upreg-
ulated and 9 were downregulated.
Among the 24 proteins, 3 with the most
significant differential expression identi-
fied above were selected and further ana-
lyzed by Western blotting (Figure 6A, B).
Consistent with two- dimensional gel
electrophoresis (2-DE). and MALDI-TOF
MS results, thioredoxin 1 and β-tubulin
protein were significantly downregu-
lated upon S100P-knockdown cancer
cells. Additionally, higher expression
protein level of RhoGDIA was found in
the S100P-knockdown cells.
DISCUSSION
Recently, S100P proteins have become
a major interest in cancer because they
are overexpressed in a variety of tumors
and their putative involvement in the
metastatic process (2–4,21). An earlier re-
port indicated that exogenous S100P in-
creased colon cancer SW480 cell prolifer-
ation and cell migration in vitro (12).
However, the role of S100P in tumorigen-
esis and metastasis of colon cancer in
vivo and its molecular mechanisms have
never been elucidated. In the current
study, we suppressed S100P expression
in colon cancer cells using lentiviral vec-
tor–mediated RNAi to determine its
exact role in colon tumorigenesis and
metastasis. Our group developed an effi-
cient and convenient lenti-shRNA system
that provided shRNA and fluorescent
marker protein coexpression and al-
lowed for easily identified transduced
cells (16). Lentiviral infection has advan-
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Figure 4. Knockdown of S100P by RNAi inhibited colon cancer cell migration and invasion
in vitro. (A) Wound-healing assay showed DLD-1 cells transduced with lenti-shLuc or lenti-
shS100P at 0 and 72 h after wounding. Bar chart showing the size of the wound at 0 and
72 h. (B) S100P knockdown inhibited cancer cell invasion in DLD-1 and SW620 cell lines.
Representative images from triplicate experiments were shown. *P < 0.05, **P < 0.01.
tages over other gene-therapy methods.
Lentivirus can infect both dividing and
nondividing cells with high efficiency,
achieve long-term stable expression of
the transgene and have low immuno-
genicity. Lenti-shS100P was used to effec-
tively knock down the expression of
S100P in colon cancer cells. We observed
a significant inhibition of cell growth by
MTT, colony formation assay and the
three-dimensional culture model in vitro
when the expression of S100P was sup-
pressed by RNAi in DLD-1 and SW620
cells. Also, knockdown of S100P drasti-
cally inhibited colon cancer cell migra-
tion and invasion in vitro, which is simi-
lar to its suggested role in pancreatic
cancer (3). Furthermore, we used an in
vivo animal model to explore the exact
role of S100P in colon cancer tumorigene-
sis and liver metastasis. We observed a
marked inhibition of colon cancer tu-
morigenicity and liver metastasis
through knockdown of S100P expression
in a nude mice model in vivo. These re-
sults indicated that S100P played a cru-
cial role in the tumorigenesis and metas-
tasis of colon cancer.
It is known that S100 proteins affect
cell function by both intracellular and ex-
tracellular mechanisms (22). S100 pro-
teins are also implicated in promoting
cancer progression through specific roles
in cell survival and apoptosis pathways
(22). Recent studies have demonstrated
that the actions of S100P are mediated by
activation of RAGE in pancreatic and
colon cancer cells (2,12,13). In the present
study, proteomic analysis was used to
identify S100P-associated downstream
proteins in colon cancer cells. Among 24
differentially expressed spots, down -
regulation of two proteins (trx-1 and
β-tubulin) and upregulation of  RhoGDIA
were confirmed to be valid after Western
blot analysis of DLD-1 cells with deletion
of S100P.
Trx-1 is a ubiquitously expressed
small redox protein that is a key regula-
tor of cellular redox balance. Trx-1 acts
as an antioxidant, growth- promoting,
 antiapo ptotic and inflammation-
 modulating protein that provides reduc-
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Figure 5. RNAi targeting S100P inhibited tumor growth and liver metastasis of colon can-
cer in vivo. (A) Knockdown of S100P inhibited tumor growth in vivo. *P < 0.05, **P < 0.01. (B)
Photographs of nude mice at 6 wks after inoculation with DLD-1 cells (n = 5). (C) Macro-
scopic appearances of liver metastasis. Suppression of S100P reduced liver metastases of
colon cancer cells in the intrasplenic injection mice model (n = 10). Metastatic tumor
nodules were identified as whitish and patchy areas (indicated by arrows). shLuc, DLD-1
colon cancer cells transduced with lenti-shLuc; shS100P, DLD-1 colon cancer cells trans-
duced with lenti-shS100P.
Figure 6. Differentially expressed protein spots among DLD-1 transduced with lenti-shLuc
or lenti-shS100P. (A) Selected regions of 2-DE gels illustrate differentially expressed proteins
among DLD-1 transduced with lenti-shLuc or lenti-shS100P. Enlarged images of interest
spots were shown. (B) Confirmation of differential expression of thioredoxin 1, β-tubulin and
RhoGDIA. Western blot analysis showed that thioredoxin 1, β-tubulin and RhoGDIA proteins
were differentially expressed among DLD-1 transduced with lenti-shLuc or lenti-shS100P.
Actin was used as an internal control.
ing equivalents and a transcriptional
regulator (23). Trx-1 expression was re-
ported to be increased in several human
cancers, including lung (24,25), liver
(26), pancreatic (27), colorectal (28,29)
and gastric carcinoma (30). Increased
trx-1 levels are associated with increased
proliferation of tumor cells, inhibition of
apoptosis, aggressive tumor growth and
decreased patient survival (23). In
human colorectal cancer, trx-1 overex-
pression is related to a poor prognosis in
patients with liver metastases (28,29).
Tubulin is the basic subunit of micro-
tubules and the α,β tubulin dimer as-
sembles forming microtubules. Micro-
tubules are important cellular targets for
anticancer therapy because of their key
role in cell  division, intracellular trans-
port, maintenance of cell shape and cel-
lular motility (31). Microtubule-targeting
drugs such as taxanes and vinca alka-
loids have been used successfully to
treat a variety of cancers in the clinic
(32). Tubulin as an antitumor target con-
tinues to attract the attention of signifi-
cant drug discovery and development
(33). RhoGDIA is a small family of pro-
teins that  includes RhoGDIA, RhoGDIB
and RhoGDIG. RhoGDIs regulate Rho
subfamily  GTPases including Rho, Rac
and Cdc42, which are important molecu-
lar switches involved in the regulation
of cytoskeletal structures that affect or
enable the regulation of cell morphology,
movement, attachment, phagocytosis
and cytokinesis. Deregulation of RhoG-
DIA was observed in human lung (34),
breast (35) and liver cancer (36). Also,
RhoGDIA was considered a candidate
metastasis suppressor for human hepa-
tocellular  carcinoma (HCC) (36), siRNA
against RhoGDIA increased the motility
and invasion of HCC cells and ectopic
expression of RhoGDIA inhibited HCC
cell migration and invasion.
In summary, the results of this study
showed that suppression of S100P using
a lentivirus RNAi expression system
could significantly inhibit colon cancer
cell growth and metastasis in vitro and in
vivo. In addition, knockdown of S100P
decreased the level of trx-1 and β-tubulin
and increased RhoGDIA expression,
which might indicate the importance of
these proteins in colon carcinogenesis via
the S100P downstream pathway. These
findings provided information that sug-
gested new therapeutic targets for the
treatment of colon cancer. However, fur-
ther studies would be necessary to clar-
ify their exact role in colon carcinogene-
sis and their applications in treating
colon cancer.
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Table 1. Differentially expressed proteins between control and S100P knockdown colon cancer cells were identified by MALDI-TOF MS.
Protein Accession number Mr/pI
a Protein score
Laminin-binding protein Gi|34234 31773.9/4.84 375
67-kDa laminin receptor Gi|250127 32746.4/4.83 374
Thioredoxin Gi|50592994 11729.7/4.82 167
Catechol-O-methyltransferase isoform S-COMT Gi|6466450 24433.4/5.15 101
Eukaryotic translation elongation factor 1 delta isoform 2 Gi|25453472 31102.8/4.9 140
ATP synthase, H + transporting, mitochondrial F1 complex, β subunit precursor Gi|32189394 56524.6/5.26 271
Ubiquilin 1 isoform 2 Gi|16753205 59182.8/5.01 181
Tubulin-specific chaperone a Gi|4759212 12846.7/5.25 157
Tubulin, β Gi|18088719 49639.9/4.75 231
Triosephosphate isomerase 1 Gi|4507645 26652.7/6.45 257
Tumor necrosis factor type 1 receptor–associated protein TRAP-1–human Gi|1082886 75294.9/8.43 335
Phosphoglycerate mutase 1 (brain) Gi|4505753 28785.8/6.67 242
Tumor protein, translationally controlled 1 Gi|4507669 19582.6/4.84 178
Rho GDP dissociation inhibitor (GDI) α Gi|4757768 23192.7/5.02 97
Tumor protein, translationally controlled 1 Gi|4507669 19582.6/4.84 74
ATP synthase, H + transporting, mitochondrial F1 complex, α subunit 1, 
cardiac muscle Gi|15030240 59771.6/9.07 190
Heterogeneous nuclear ribonucleoprotein K isoform α Gi|14165437 50996.4/5.19 188
Chaperonin containing TCP1, subunit 5 (epsilon) Gi|24307939 59632.8/5.45 511
NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75 kDa 
(NADH–coenzyme Q reductase) Gi|21411235 79388.5/5.8 351
RuvB-like 2 Gi|5730023 51124.6/5.49 328
T-complex protein 1 isoform α Gi|57863257 60305.6/5.8 261
Aldehyde dehydrogenase 1B1 precursor Gi|25777730 57213.2/6.55 375
SFN protein Gi|16306737 24321.0/4.77 147
Protein disulfide isomerase-related protein 5 Gi|1710248 46170.2/4.95 345
aMolecular mass/isoelectric point (Mr/pI).
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